昆药集团(600422.SH)：上半年净利润1.98亿元，同比下降26.88%

Core Viewpoint - Kunming Pharmaceutical Group (600422.SH) reported a decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating income of 3.351 billion yuan, a year-on-year decrease of 11.68% [1] - The net profit attributable to shareholders was 198 million yuan, down 26.88% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 150 million yuan, reflecting a year-on-year decline of 5.57% [1] - Basic earnings per share were reported at 0.26 yuan [1]